Seres Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, dedicated to developing microbiome-based therapeutics. The company’s core technology platform harnesses defined consortia of live bacteria to restore and maintain healthy microbial ecosystems in the human gastrointestinal tract. By targeting the underlying microbial imbalances associated with various diseases, Seres seeks to offer novel treatment approaches where traditional therapies have shown limited success.
At the forefront of Seres’s pipeline is SER-109, an investigational microbiome therapeutic designed to prevent recurrent Clostridioides difficile infection by reestablishing colonization resistance. Additional programs include SER-287 for ulcerative colitis and SER-401, aimed at enhancing the efficacy of cancer immunotherapies. Each candidate reflects Seres’s strategy of addressing inflammatory and infectious diseases through precise modulation of the gut microbiome.
Since its founding in 2010, Seres has built a network of research collaborations and strategic partnerships, notably with Nestlé Health Science, to advance clinical development and manufacturing capabilities. The company conducts trials across the United States and Europe, supported by specialized laboratories and scalable production facilities designed for complex microbial therapies.
Leadership at Seres is led by Chief Executive Officer David A. Mitchell, M.D., whose background in immunology and drug development underpins the company’s scientific direction. The management team and board of directors comprise experts in microbiology, bioprocessing and clinical research, collectively guiding Seres’s mission to pioneer therapeutics that harness the power of the human microbiome.
AI Generated. May Contain Errors.
